Mark Stejbach
Director at Indivior Pharmaceuticals, Inc. (INDV) since January 2026
Mark Stejbach has filed 6 insider reports with the SEC since June 2021, as director at Indivior Pharmaceuticals, Inc. (INDV) and director at Flexion Therapeutics Inc (FLXN). In the last 12 months Mark Stejbach bought $27.4K of stock on the open market. The latest filing, on May 14, 2026, reports grant or award at Indivior Pharmaceuticals, Inc. (INDV).
- Filings
- 6
- Companies
- 2
- Bought on market
- $27.4K
- Sold on market
- None
Companies where Mark Stejbach is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince January 2026 | 27,087 | $27.4K | $35.39 | $36.28+2.5% | May 14, 2026 | ||
| Director | 0 | $23.5614 | Nov 19, 2021 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- May 13, 2026INDVDirector Stejbach Mark was granted 6,518 shares, increasing direct ownership by 32% to 27,087 unitsForm 4Grant or award
- Jan 26, 2026INDVDirector Stejbach Mark was granted 3,722 shares, increasing direct ownership by 22% to 20,569 unitsForm 4Grant or award
- Jan 5, 2026+$27.4KINDVDirector Stejbach Mark bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 5% to 16,847 unitsForm 4Open-market purchase
- Jan 1, 2026INDVNew insider Stejbach Mark claimed ownership of 16,072 units of Ordinary SharesForm 3New insider
- Nov 19, 2021FLXNSEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxesForm 4Sale back to the company
- Jun 24, 2021FLXNSEC Form 4: Stejbach Mark was granted 4,500 units of Common Stock, increasing direct ownership by 55% to 12,631 unitsForm 4Grant or award
Compare Mark Stejbach with
- Mark Stejbach vs Frank Mottola1 shared
- Mark Stejbach vs William Todd Horich1 shared
- Mark Stejbach vs Timothy C Dec1 shared
- Mark Stejbach vs Carrolee Barlow1 shared
- Mark Stejbach vs Padmanabh P. Bhatt1 shared
- Mark Stejbach vs Bethany Sensenig1 shared
Other insiders at the same companies
- Frank MottolaINDV
- William Todd HorichINDV
- Timothy C DecINDV
- Carrolee BarlowINDV
- Padmanabh P. BhattINDV
- Bethany SensenigINDV
- Georges GemayelINDV
- Jack A. KhattarINDV
- Jonathan RubinINDV
- Woodrow D AndersonINDV
- Christian HeidbrederINDV
- Joseph CiaffoniINDV
- Ryan PreblickINDV
- Juliet ThompsonINDV
- Keith HumphreysINDV
- Stuart A KingsleyINDV
Questions about Mark Stejbach
- What is Mark Stejbach's role at Indivior Pharmaceuticals, Inc.?
- Mark Stejbach reports to the SEC as director at Indivior Pharmaceuticals, Inc. (INDV), according to the latest filing on May 14, 2026. Mark Stejbach has also filed as director at Flexion Therapeutics Inc (FLXN).
- How many shares does Mark Stejbach own?
- After the latest filing that states it, Mark Stejbach directly owned 27,087 shares of Indivior Pharmaceuticals, Inc. (INDV). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Mark Stejbach bought or sold stock recently?
- The most recent open-market purchase was on January 5, 2026: bought 775 shares of Indivior PLC (INDV) for $27.4K at an average of $35.39.
- How do I get alerts when Mark Stejbach files?
- Follow Mark Stejbach on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Mark Stejbach (SEC CIK 0001487937). Totals count each trade once, skipping amendments whose original is on file, from Jun 28, 2021 on. View on SEC EDGAR